Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by NotinKansason May 31, 2023 10:24am
168 Views
Post# 35472331

RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements
I agree with your sentiment, but perverse and subversive I wouldn’t call it. The plots are a more comprehensive and transparent way of sharing data than the summary tables they also provide. From the last plot, for example, you can derive that someone who achieved an initial CR at 90 days, has a 62% chance of remaining CR all the way through 450 days, which is something rather relevant in light of the trial’s second objective, and something you would not be able to derive from the summary tables.

To help us laymen, TLT should simply explain in their communications how the swimmers plots are construed. Maybe someone with access to the team can suggest it to them.
<< Previous
Bullboard Posts
Next >>